

# Modelling of Cancer Morbidity Risk in a Bayesian Framework

Ayşe Arık

Heriot-Watt University, Edinburgh

Research Fellow

joint work with George Streftaris and Erençül Dodd

under [Modelling, Measurement and Management of Longevity and Morbidity Risk](#) research programme funded by the ARC

EAJ 2018 Conference, 10 September 2018



- 1 Aim of the Study
- 2 Data
- 3 All Cancer Incidences
- 4 Lung Cancer
- 5 Prostate Cancer
- 6 Breast Cancer
- 7 A Comparison bw Population Incidence Rates and CII Rates
- 8 Summary



# Aim of the Study

## The main purpose of the study

- 1 Investigate the dynamics of various types of population cancer risk
  - under a Bayesian setting by employing generalised linear model structures
  - using cancer registration numbers in England
- 2 Compare population incidence rates with the CII rates



## Cancer registration data for England provided by Office for National Statistics (ONS)

- 1 International Statistical Classification of Diseases (ICD): ICD 8, ICD 9 and ICD 10
- 2 age from zero to 95+
- 3 year from 1971 through 2015
- 4 region ?
- 5 gender



# All Cancer Incidences in England

⇒ Bayesian model

$$C_i | \theta_i \sim \text{Poisson}(E_i \theta_i)$$

$$\theta_i \sim \text{Lognormal}(\mu_i, \sigma^2)$$

$$\mu_i = \beta_0 + \beta_{1,j} x_j + \beta_{2,k} y_k + \beta_{3,g} x_g + \beta_{4,j,g} x_j x_g$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.001)$$


$$\beta\text{'s} \sim \text{Normal}(0, 10^4),$$

$i = 1, \dots, 1080$ ;  $k = 1, \dots, 36$ ;  $j = 1, \dots, 15$  and  $g = 1, 2$ .

Model	age	year	age:year	gender	age:gender	BIC
1	cont.	cont.	X	factor	X	1131204
2	cont.	cont.	✓	factor	X	1130858
3	cont.	factor	X	factor	X	1126715
4	cont.	factor	✓	factor	X	1126402
5	factor	cont.	X	factor	X	360975
6	factor	cont.	✓	factor	X	355419
7	factor	cont.	✓	factor	✓	350386
8	cont.	factor	✓	factor	✓	817914
9	factor	factor	X	factor	✓	37229
10	factor	factor	✓	factor	X	351360



# All Cancer Incidences in England





Actual and fitted incidence rates of all cancer types without carcinoma in situ  
fitted incidence rates as solid lines & crude rates as dots

- An increasing trend for all ages.



# All Cancer Incidences in England



incidence rates for females from ages 47 to 62  
for years 1980, 1995, 2000 and 2015  
fitted incidence rates as solid lines

- Ageing is a fundamental factor for cancer.



# Lung Cancer in England

⇒ Bayesian model

$$C_i | \theta_i \sim \text{Poisson}(E_i \theta_i)$$

$$\theta_i \sim \text{Lognormal}(\mu_i, \sigma^2)$$

$$\mu_i = \beta_0 + \beta_1 x + \beta_2 x^2 + \beta_3 x^3 + \beta_4 y + \beta_5 xy + \beta_{6,g} x_g + \beta_{7,g} x_g y + \beta_{8,g} x_g x$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.001)$$

$$\beta\text{'s} \sim \text{Normal}(0, 10^4),$$


$i = 1, \dots, 648$  and  $g = 1, 2$ .

Model	age	year	age:year	gender	gender:year	age <sup>2</sup>	age <sup>3</sup>	gender:age	DIC
12	Cont.	Cont.	✓	Factor	✓	✓	✓	✓	7148







# Lung Cancer in England



Actual and fitted incidence rates of malignant neoplasm of trachea, bronchus and lung  
fitted incidence rates as solid lines & crude rates as dots

- A narrowing gap bw males & females with different trends due to different smoking patterns.

# Lung Cancer in England



fitted incidence rates as solid lines

- An opposite trend for males and females.



# Prostate Cancer in England

⇒ Bayesian model

$$C_i | \theta_i \sim \text{Poisson}(E_i \theta_i)$$

$$\theta_i \sim \text{Lognormal}(\mu_i, \sigma^2)$$

$$\mu_i = \beta_0 + \beta_1 x + \beta_2 x^2 + \beta_3 x^3 + \beta_4 y + \beta_5 y^2 + \beta_6 y^3 + \beta_7 y^4 + \beta_8 xy$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.001)$$


$$\beta\text{'s} \sim \text{Normal}(0, 10^4),$$

$i = 1, \dots, 324.$

Model	age	year	age:year	year <sup>2</sup>	year <sup>3</sup>	year <sup>4</sup>	age <sup>2</sup>	age <sup>3</sup>	DIC
14	cont.	cont.	✓	✓	✓	✓	✓	✓	3580



# Prostate Cancer in England





Actual and fitted incidence rates of malignant neoplasm of prostate  
fitted incidence rates as solid lines & crude rates as dots

- PSA testing started to be used in the UK in the early 1990s.
- The second increase after 2006 with a peak in 2013.



# Prostate Cancer in England



Actual and fitted incidence rates of malignant neoplasm of prostate for years 1980, 1990, 2006 and 2013 fitted incidence rates as solid lines



# Breast Cancer in England

⇒ Bayesian model

$$C_i | \theta_i \sim \text{Poisson}(E_i \theta_i)$$

$$\theta_i \sim \text{Lognormal}(\mu_i, \sigma^2)$$

$$\mu_i = \beta_0 + \beta_{1,j} x_j + \beta_2 y + \beta_{3,j} x_j y$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.001)$$



$$\beta\text{'s} \sim \text{Normal}(0, 10^4),$$

$i = 1, \dots, 540$  and  $j = 1, \dots, 15$ .

Model	age	year	age:year	DIC
6	factor	cont.	✓	5616



# Breast Cancer in England





Actual and fitted incidence rates of malignant neoplasm of breast  
fitted incidence rates as solid lines & crude rates as dots

- NHSBSP began in 1988, targeted women between ages 50 and 64.
- After 2005, screening offered for women between ages 50 and 70.



# Breast Cancer in England




Actual and fitted incidence rates of malignant neoplasm of breast  
for years 1980, 1988 and 2005  
fitted incidence rates as solid lines





# A Comparison between Population Incidence Rates and CII Rates



fitted population incidence rates (ONS data) as solid lines &  
fitted CII rates (CMI data) as dashed lines

- incidence rates  $>$  CII rates
- Cancer rates are higher for socio-economically deprived groups.



- An increasing trend for all cancer types for all age groups.
- An adverse trend in lung cancer for different genders.
- An increasing trend both in prostate and breast cancers.
- Population incidence rates are higher than the insurance rates.



- 1 CII claims settled bw 1999 and 2005 by Continuous Mortality Investigation (CMI) in the UK.
- 2 Office for National Statistics. Cancer registration statistics, England, 2008, 2009, 2011, 2013 and 2016.
- 3 E. Ozkok, G. Streftaris, H.R. Waters, and A.D. Wilkie. Modelling critical illness claim diagnosis rates I: Methodology. Scandinavian Actuarial Journal, Vol:5, pp 43-457, 2014a.
- 4 E. Ozkok, G. Streftaris, H.R. Waters, and A.D. Wilkie. Modelling critical illness claim diagnosis rates II: Results. Scandinavian Actuarial Journal, Vol:5, pp 458-482, 2014b.





# Thank You!

## Questions?

e-mail: [A.ARIK@hw.ac.uk](mailto:A.ARIK@hw.ac.uk)